Out of 13 analysts covering Shire plc (ADR) (NASDAQ:SHPG), 12 rate it “Buy”, 0 “Sell”, while 2 “Hold”. This means 86% are positive. Shire plc (ADR) was the topic in 20 analyst reports since July 22, 2015 according to StockzIntelligence Inc. Below is a list of Shire PLC (ADR) (NASDAQ:SHPG) latest ratings and price target changes.
18/01/2016 Broker: Bank of America Old Rating: Neutral New Rating: Buy Upgrade
15/01/2016 Broker: Bank of America Old Rating: Neutral New Rating: Buy Upgrade
12/01/2016 Broker: William Blair Rating: Old Target: $248.00 New Target: $210.00 Target Down
12/01/2016 Broker: Credit Suisse Old Rating: Neutral New Rating: Outperform Upgrade
12/01/2016 Broker: RBC Capital Markets Rating: Sector Perform Old Target: $248.0 New Target: $240.0 Maintain
04/12/2015 Broker: JP Morgan Rating: Overweight Old Target: $305.00 New Target: $275.00 Target Down
17/11/2015 Broker: Leerink Swann Old Rating: Market Perform New Rating: Outperform Upgrade
03/11/2015 Broker: HSBC Old Rating: Hold New Rating: Buy Upgrade
27/10/2015 Broker: HSBC Old Rating: Hold New Rating: Buy Upgrade
26/10/2015 Broker: Jefferies Rating: Buy Old Target: $299.00 New Target: $259.00 Target Down
The stock increased 0.12% or $0.2 on March 4, hitting $160.39. Shire PLC (ADR) (NASDAQ:SHPG) has declined 38.90% since July 30, 2015 and is downtrending. It has underperformed by 33.75% the S&P500.
Shire plc is a biopharmaceutical company. The company has a market cap of $31.81 billion. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other specialty conditions. It has 23.7 P/E ratio. The Firm commercializes its products in the areas of Neuroscience, Gastrointestinal , Rare Diseases and Other therapeutic areas.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.